Buse Cagla ARI

Dr. Buse Cagla ARI

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2021 in Acta Neurologica Belgica
Verified
Journal Article
Open access
PDF file
GKGulay Ozgen Kenangil
Gulay Ozgen Kenangil
BABuse Cagla ARI
Buse Cagla ARI
CGCagan Guler
Cagan Guler
MDMustafa Kemal Demir
Mustafa Kemal Demir

31 July 2019 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
GKG. Kenangil
G. Kenangil
BABuse Cagla ARI
Buse Cagla ARI
FKF. A. Kaya
F. A. Kaya
MDM. Demir
M. Demir
FDF. M. Domac
F. M. Domac

1 September 2020 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
BABuse Cagla ARI
Buse Cagla ARI
FDFusun Mayda Domac
Fusun Mayda Domac
SUSamiye Ulutas
Samiye Ulutas

1 January 2020 in Neurology India
Verified
Journal Article
Closed access
BABuse Cagla ARI
Buse Cagla ARI
FDFusunMayda Domac
FusunMayda Domac
GKGulayOzgen Kenangil
GulayOzgen Kenangil
Ecreases the release of several neurotransmitters. In this case report, we present a 53-year-old female patient with the signs of parkinsonism following pregabalin treatment. Drug-induced parkinsonism was diagnosed based on the clinical features, investigations, and resolution of the complaints. The symptoms relieved after the treatment stopped at a follow-up of 10 days. Due to the rare report of pregabalin-induced parkinsonism, we aim to enhance clinicians' awareness of pregabalin's probable side effects....

1 January 2022 in Ideggyogyaszati Szemle
Verified
Journal Article
Closed access
BABuse Cagla ARI
Buse Cagla ARI
ETEsma Kobak Tur
Esma Kobak Tur
FDFusun Mayda Domac
Fusun Mayda Domac
GKGulay Ozgen Kenangil
Gulay Ozgen Kenangil
Oxidative stress has been associated as an essential contributor to the development of neurodegenerative diseases. Recent developments in the field of Parkinson’s Disease (PD) pathophysiology have led to a renewed interest in this field. As an antioxidant, uric acid (UA) has arisen as a potential neuroprotectant. Higher concentrations of UA are linked to reducing the risk of the development of the disease and preventing its progression. However, the expositions are unsatisfactory because the outcomes of these reports have not been consistent. This study is set out to assess the association of whether lower UA concentrations increased the PD risk by investigating its relationship with patients’ demographic and clinical data, and to determine whether previous studies are compatible with the Turkish-sampled population. Furthermore, we aimed to determine UA’s probability of being an early-stage diagnostic marker. A total of 305 patients and 100 healthy controls were included. Serum UA levels of patients and controls were compared with clinical features. We classified the patients into three motor subtypes and determined the disease severity by modified Hoehn&Yahr Staging Scale (mH&Y) and Unified Parkinson’s Disease Rating Scale (UPDRS). Standardized Mini-Mental State Examination (MMSE-TR) was assessed for cognition. There were not any significant differences of age and sex between patients and controls (p=0.030, p=0.132). The mean UA was 5.06±1.33 mg/dL in patients and 5.46±1.44 in controls, and a statistical significance was detected (p=0.022). The mean MMSE-TR were 24.83±4.35 in patients and 27.09±2.13 in controls, and statictical significance was revealed (p=0.001). The mean duration of the disease was 6.31±4.16 years, mean UPDRS scores were 59.74±22.33, and mH&Y scores were 2.29±0.91. In binary comparisons, patients with tremor-dominant motor subtype had lower UA concentrations than controls (p=0.014). ROC curve analysis revealed UA’s cut-off as ≤9.15, the specificity was 99.3, the sensitivity was 10.0, and the area under the curve was 0.576 (p<0.005). Regression analysis revealed age as an independent risk factor on UA values. Oxidative stress might be a factor in the development of PD, and UA may be a possible prospective protecting factor in the clinical course of the disease. However, it does not affect the severity. Our results support that lower uric acid concentrations are associated with PD; however, it is not a powerful indicator for predicting PD risk. As we reveal more about UA and its effect in further investigations, its significant role will become well-defined.

2 November 2023 in Cureus
Verified
Journal Article
Open access
PDF file
BABuse Cagla ARI
Buse Cagla ARI
ESElifnaz Sahin
Elifnaz Sahin
Introduction: In the process of differential diagnosis concerning chronic abdominal wall pain (CAWP), several conditions are typically considered, including abdominal wall hernias, endometriosis, thoracic nerve radiculopathies, xiphoidalgia, and lower rib pain syndromes. Notwithstanding these, there exists an additional condition that is often overlooked initially: anterior cutaneous nerve entrapment syndrome (ACNES). This syndrome is characterized by the entrapment of cutaneous nerve branches responsible for supplying the abdominal wall. The diagnostic procedure for this condition can present notable challenges. Case presentation: The subject of concern was a male patient aged 30, who presented with persistent CAWP. Despite conducting comprehensive analyses of his blood, urine, and imaging studies, no anomalies were detected. However, he exhibited positive results for the pinch test and Carnett's sign. Based on the outcomes of his clinical assessment, the patient received a diagnosis of ACNES. Subsequent administration of gabapentin resulted in a notable alleviation of his symptoms. Conclusions: This case report highlights the referral of a patient to a neurology clinic owing to abdominal wall pain. Given the rarity of ACNES reports, our objective was to delineate the findings of our patient, with the aim of augmenting clinicians' understanding of this condition.